Breaking AI & Tech News Analyzed

The Lead The World Health Organization (WHO) has approved the first malaria treatment for babies, marking a significant milestone in the global fight against the disease. Coartem Baby, developed by Novartis and the Medicines for Malaria Venture (MMV), is designed for infants as small as 2kg (4.4lb) and comes in sweet cherry-flavoured tablets that can be dissolved into liquids, including breast milk. The Event Details Coartem Baby contains two antimalarial drugs, artemether and lumefantrine. The treatment has been shown to be safe and effective for newborns and young infants, addressing a critical gap in malaria care. According to the WHO, up to 18% of children under six months in parts of Africa are infected with malaria, but there has historically been no safe treatment for the smallest of them. The Data Analysis Malaria remains a significant public health challenge, particularly in sub-Saharan Africa. In 2024, there were 610,000 deaths from malaria, about three-quarters of which were under-fives in Africa. The approval of Coartem Baby is expected to significantly impact malaria treatment and prevention efforts, particularly in regions with high rates of malaria. The Impact Analysis The introduction of Coartem Baby is a major breakthrough in the fight against malaria. Dr Tedros Adhanom Ghebreyesus, the WHO director general, noted that "for centuries, malaria has stolen children from their parents, and health, wealth and hope from communities." The approval of this treatment offers new hope for communities affected by malaria and brings the global health community closer to achieving its goal of eliminating the disease. The Prediction With the WHO prequalification of Coartem Baby, public-sector procurement of the treatment is expected to increase in many countries with high rates of malaria, particularly in sub-Saharan Africa. Novartis has committed to making the treatment available "on a largely not-for-profit basis in malaria-endemic regions." As more countries introduce Coartem Baby into their health systems, the impact on malaria-related mortality and morbidity is expected to be significant.

Scotland has taken a significant step in the early detection and treatment of spinal muscular atrophy (SMA), a rare genetic condition that causes progressive muscle wastage, by becoming the first part of the UK to screen newborn babies for the condition.The screening, which is part of the existing heel prick test offered to all parents in Scotland about four days after birth, is funded by the Scottish government and pharmaceutical company Novartis. The goal is to assess how well screening can detect SMA earlier, allowing babies to receive treatment as soon as possible.SMA affects an estimated 1 in 14,000 births worldwide and impacts movement, breathing, and swallowing. Without treatment, it can limit life expectancy to two years. The condition was brought to wider attention after former Little Mix singer Jesy Nelson revealed in January that her twin daughters had been diagnosed with SMA.Campaigners, who have long advocated for newborn testing, hope the Scottish pilot will result in approval for the heel prick test across the UK. Giles Lomax, chief executive of SMA UK, said the screening pilot in Scotland would be “a huge impetus for other parts of the UK to speed up their own testing plans”. He hopes the Scotland trial will provide data that would convince the UK National Screening Committee to approve UK-wide testing.There is no cure for SMA, but there are now three NHS-funded drug treatments available. Lomax emphasized that with these treatments and newborn screening, “the future for anyone diagnosed with SMA is very different compared to their peers who were diagnosed symptomatically. It basically gives children the life they deserve.”